Etavopivat
An investigational treatment for Sickle Cell Disease.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Etavopivat wherever you encounter it, plus the key facts at a glance.
- Generic name
- Etavopivat
- Development code
- FT-4202
- Drug class
- Pyruvate kinase activator
- Manufacturer
- Novo Nordisk (from its 2022 acquisition of Forma Therapeutics)
- How it's taken
- By mouth, once a day, in a trial only
An investigational once-daily medicine taken by mouth that switches on pyruvate kinase, an energy enzyme inside red blood cells, to help them resist sickling and last longer[1].
- Novo Nordisk announced on November 13, 2026 that it had submitted a New Drug Application to the FDA and a Marketing Authorization Application to the European Medicines Agency for people with sickle cell disease aged 12 and older, and Novo expects the FDA to act in 2027[1].
- Novo has not announced whether the FDA has accepted the application for review or set a decision date.
- Etavopivat is not approved anywhere and is available only in clinical trials.
We'll email you when the FDA acts on Etavopivat and when new trials for Sickle Cell Disease open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Etavopivat fits
Etavopivat is an experimental once-daily oral pyruvate kinase activator from Novo Nordisk that was submitted to the FDA and the European Medicines Agency in November 2026 for people with sickle cell disease aged 12 and older[1].
- Hydroxyurea, sold as Droxia, is approved to reduce painful crises and the need for blood transfusions[11].
- L-glutamine (Endari) is approved to reduce acute complications of sickle cell disease in people 5 and older, and crizanlizumab (Adakveo) is approved to reduce pain crises in people 16 and older, though the Adakveo label says a later trial, STAND, did not establish its efficacy[12][13].
- Casgevy and Lyfgenia are one-time gene therapies given after chemotherapy in a transplant center, and the Lyfgenia label carries a boxed warning for blood cancer[14][15].
- Voxelotor (Oxbryta) is no longer available, because Pfizer withdrew it worldwide on September 25, 2024[16].
- Mitapivat, another pyruvate kinase activator approved for other anemias, is under FDA review for sickle cell disease with a goal date of February 1, 2027, according to Agios[17].
- No trial has compared etavopivat directly with mitapivat or any other sickle cell medicine.
- A question to bring to a hematologist is whether a person's pain crisis history and current medicines would fit the rules of HIBISCUS 2.
How Etavopivat works
In sickle cell disease, an inherited change in hemoglobin makes it stick together into long strands when it lets go of oxygen, which bends red blood cells into a sickle shape so they break apart early and block small blood vessels. Etavopivat switches on PKR, the red blood cell form of pyruvate kinase, the enzyme behind the last step of energy production in red blood cells[1].
Novo Nordisk says this is meant to lower 2,3-DPG, a molecule that loosens hemoglobin's grip on oxygen, so hemoglobin holds oxygen more tightly and is less likely to form strands[1][3]. Novo says it is also meant to raise ATP, the cell's energy supply, which helps keep the red cell's outer membrane flexible and helps the cell survive longer[1].
In a Phase 1 study published in Blood Advances in 2024, 12 weeks of etavopivat raised ATP, lowered 2,3-DPG and lowered markers of red cell breakdown in people with sickle cell disease[3].
Clinical trial results
HIBISCUS (NCT04624659) is a Phase 2/3 trial in which the Phase 3 dose was chosen after a 12-week Phase 2 readout[1][4]. Novo Nordisk describes its 52-week Phase 3 comparison as etavopivat 400mg against placebo in 385 people aged 12 and older who had 2 to 15 pain crises, also called vaso-occlusive crises, in the year before joining, with standard care allowed throughout[2][1].
ClinicalTrials.gov lists HIBISCUS as active and no longer recruiting, and its rules allowed people already on a stable dose of hydroxyurea, crizanlizumab or L-glutamine[4]. Novo reported on April 20, 2026 that HIBISCUS met both of its main goals: the yearly rate of pain crises was 27% lower than on placebo, and 48.7% on etavopivat had their hemoglobin rise by more than 1g/dL at week 24, against 7.2% on placebo[2].
The median time to a first pain crisis was 38.4 weeks on etavopivat against 20.9 weeks on placebo, and an exploratory analysis found a lower risk of needing a blood transfusion[2]. Full results have not been published.
HIBISCUS 2 (NCT06612268) is a recruiting Phase 3 trial planned for about 510 people aged 12 and older, assigned by chance to etavopivat or placebo with neither participants nor doctors knowing which, and its main measure is the number of pain crises that needed medical care over 52 weeks[5]. ClinicalTrials.gov lists an estimated primary completion date of August 2027[5].
FLORAL (NCT06609226) is a recruiting Phase 3 open-label extension that gives etavopivat long term to people with sickle cell disease or thalassemia[6]. In children, HIBISCUS KIDS (NCT06198712) is a recruiting Phase 2 study of drug levels and safety, and HIBISCUS 3 (NCT05953584) is a recruiting Phase 2 open-label study of blood flow speeds in the brain, measured by transcranial Doppler ultrasound, in children at higher risk of a first stroke[7][8].
Main registered trial: NCT06612268 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.
Side effects and safety
Novo Nordisk said in April 2026 that etavopivat appeared well tolerated in the HIBISCUS trial, with a topline safety profile in line with earlier etavopivat trials, and it has not published side effect rates from that trial[2]. Novo says full results will be presented at a scientific meeting and published in a peer-reviewed journal[1].
In the open-label part of the Phase 1 study, where 15 people with sickle cell disease took 400mg once a day for 12 weeks, side effects were mostly grade 1 or 2, 5 people had a serious adverse event, and a sickle cell pain episode was the most common adverse event, in 7 people[3]. An adverse event is any medical problem during a trial, whether or not the drug caused it. A full list of side effects would come from an FDA label if the drug is approved.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Etavopivat
Taken by mouth once a day, in trials only[1]. Novo Nordisk's HIBISCUS Phase 3 comparison used a dose of 400mg once a day[2]. Any approved dose would be set by an FDA label.
Development history
Forma Therapeutics developed etavopivat under the code FT-4202, and its first study in people with sickle cell disease, a Phase 1 trial (NCT03815695), began in December 2018[3][9]. HIBISCUS began in January 2021[4]. Novo Nordisk gained etavopivat when it acquired Forma Therapeutics in 2022[1]. A Forma Phase 2 study in anemia from myelodysplastic syndromes (NCT05568225) was terminated in July 2024[10].
Novo announced the HIBISCUS results on April 20, 2026 and its FDA and EMA submissions on November 13, 2026[2][1]. Novo says the FDA has granted etavopivat Fast Track, Rare Pediatric Disease and Orphan Drug designations, and the European Commission has granted it orphan designation for sickle cell disease[1].
Access and eligibility
Not approved, and available only in a trial. HIBISCUS 2 takes people aged 12 and older with confirmed sickle cell disease who had 2 to 15 documented pain crises in the 12 months before screening and a hemoglobin of 5.0 to 10.0g/dL[5]. It leaves out people on regularly scheduled blood transfusions or with 6 or more transfusions in the past 12 months, people who used voxelotor or a similar drug, a selectin blocker such as crizanlizumab, or erythropoietin within 28 days, people who used medicines that strongly or moderately speed up the CYP3A4 liver enzyme within 2 weeks, and people who have had a cell-based therapy[5]. ClinicalTrials.gov lists 43 recruiting US sites in 23 states and Washington, DC, as of November 15, 2026[5].
Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.
Explore Sickle Cell Disease trials
Other Sickle Cell Disease treatments
Common questions about Etavopivat
▸What is Etavopivat?
An investigational once-daily medicine taken by mouth that switches on pyruvate kinase, an energy enzyme inside red blood cells, to help them resist sickling and last longer[1]. Novo Nordisk announced on November 13, 2026 that it had submitted a New Drug Application to the FDA and a Marketing Authorization Application to the European Medicines Agency for people with sickle cell disease aged 12 and older, and Novo expects the FDA to act in 2027[1]. Novo has not announced whether the FDA has accepted the application for review or set a decision date. Etavopivat is not approved anywhere and is available only in clinical trials.
▸How does Etavopivat work?
In sickle cell disease, an inherited change in hemoglobin makes it stick together into long strands when it lets go of oxygen, which bends red blood cells into a sickle shape so they break apart early and block small blood vessels. Etavopivat switches on PKR, the red blood cell form of pyruvate kinase, the enzyme behind the last step of energy production in red blood cells[1]. Novo Nordisk says this is meant to lower 2,3-DPG, a molecule that loosens hemoglobin's grip on oxygen, so hemoglobin holds oxygen more tightly and is less likely to form strands[1][3]. Novo says it is also meant to raise ATP, the cell's energy supply, which helps keep the red cell's outer membrane flexible and helps the cell survive longer[1]. In a Phase 1 study published in Blood Advances in 2024, 12 weeks of etavopivat raised ATP, lowered 2,3-DPG and lowered markers of red cell breakdown in people with sickle cell disease[3].
▸What are the side effects of Etavopivat?
Novo Nordisk said in April 2026 that etavopivat appeared well tolerated in the HIBISCUS trial, with a topline safety profile in line with earlier etavopivat trials, and it has not published side effect rates from that trial[2]. Novo says full results will be presented at a scientific meeting and published in a peer-reviewed journal[1]. In the open-label part of the Phase 1 study, where 15 people with sickle cell disease took 400mg once a day for 12 weeks, side effects were mostly grade 1 or 2, 5 people had a serious adverse event, and a sickle cell pain episode was the most common adverse event, in 7 people[3]. An adverse event is any medical problem during a trial, whether or not the drug caused it. A full list of side effects would come from an FDA label if the drug is approved.
▸How is Etavopivat taken?
▸Is Etavopivat FDA approved?
Etavopivat is currently in phase 3 clinical trials for Sickle Cell Disease. It has not yet received FDA approval.
▸Is etavopivat FDA approved?
No. Etavopivat is an experimental medicine, and Novo Nordisk announced on November 13, 2026 that it had submitted it to the FDA for sickle cell disease in people 12 and older[1].
FDA timing: Novo expects the FDA to act in 2027 and has not announced a decision date.
Europe: an application was also sent to the European Medicines Agency.
Now: available only in clinical trials.
Source: Novo Nordisk, November 13, 2026
▸What did the HIBISCUS trial show?
Novo Nordisk reported that HIBISCUS met both main goals in 385 people aged 12 and older[2].
Pain crises: 27% lower yearly rate than placebo.
Hemoglobin: 48.7% had a rise of more than 1g/dL at week 24, against 7.2% on placebo.
First crisis: a median of 38.4 weeks on etavopivat against 20.9 weeks on placebo.
Full results: not yet published.
Source: Novo Nordisk, April 20, 2026
▸How is etavopivat different from mitapivat?
Both activate pyruvate kinase in red blood cells, and neither has been compared with the other in a trial[1][17].
Etavopivat: once a day by mouth, from Novo Nordisk, submitted to the FDA for sickle cell disease in November 2026.
Mitapivat: approved for other anemias and under FDA review for sickle cell disease, with a goal date of February 1, 2027, according to Agios.
Source: Novo Nordisk, November 13, 2026 and Agios, October 30, 2026
▸Who can join an etavopivat trial?
HIBISCUS 2 is recruiting people aged 12 and older with sickle cell disease who had 2 to 15 documented pain crises in the past year[5].
Hemoglobin: 5.0 to 10.0g/dL at screening.
Not eligible: people on regularly scheduled transfusions, and people who recently used crizanlizumab, voxelotor or erythropoietin.
Where: 43 recruiting US sites as of November 15, 2026.
Children: separate studies, HIBISCUS KIDS and HIBISCUS 3, are recruiting, at sites outside the US.
Source: ClinicalTrials.gov NCT06612268
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Novo Nordisk via PR Newswire · 2026-11-13. Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval. https://www.prnewswire.com/news-releases/novo-submits-etavopivat-an-investigational-once-daily-therapy-for-adolescents-and-adults-living-with-sickle-cell-disease-to-the-fda-and-ema-for-approval-302938350.html
- Novo Nordisk · 2026-04-20. Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916533
- Blood Advances via PubMed · 2024-08-27. Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease. https://pubmed.ncbi.nlm.nih.gov/38640200/
- ClinicalTrials.gov. A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS). https://clinicaltrials.gov/study/NCT04624659
- ClinicalTrials.gov. A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease. https://clinicaltrials.gov/study/NCT06612268
- ClinicalTrials.gov. A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia. https://clinicaltrials.gov/study/NCT06609226
- ClinicalTrials.gov. A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease. https://clinicaltrials.gov/study/NCT06198712
- ClinicalTrials.gov. A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke. https://clinicaltrials.gov/study/NCT05953584
- ClinicalTrials.gov. A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients. https://clinicaltrials.gov/study/NCT03815695
- ClinicalTrials.gov. A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS). https://clinicaltrials.gov/study/NCT05568225
- DailyMed · 2025-09-12. DROXIA- hydroxyurea capsule. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ad13dc6-a2ab-4308-96b3-7c642c92cc23
- U.S. National Library of Medicine, DailyMed · 2025-06. ENDARI (L-glutamine oral powder): prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5a783f4-12ef-4326-8faa-40018e45ba3b
- U.S. National Library of Medicine, DailyMed · 2026-06. ADAKVEO (crizanlizumab-tmca) injection: prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2b7f8b4-fe9a-4a86-8129-9e43f99a20c6
- U.S. National Library of Medicine, DailyMed. CASGEVY (exagamglogene autotemcel): prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c3e12ad-e2fe-4d3f-a630-ea7364d9e846
- DailyMed · 2026-07-21. LYFGENIA- lovotibeglogene autotemcel suspension. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d1b475e-5781-2bd1-e063-6294a90a7311
- Pfizer · 2024-09-25. Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease
- Agios Pharmaceuticals · 2026-10-30. Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA. https://investor.agios.com/news-releases/news-release-details/agios-announces-new-pdufa-goal-date-february-1-2027-mitapivat